Drug intelligence / Profile preview

Oncovix

Development stage: Preclinical
Lead developer: OGRD Alliance
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

Oncovix (also referred to as OncoVix) is an experimental cancer immunotherapy developed by OGRD Alliance, utilizing the PLPC-DB (Phospholipoproteomic Complex) platform. It is a non-cellular, biologic therapy based on lyophilized dendritic exosomes designed for precision oncological treatment. The mechanism of action involves the modulation of the tumor microenvironment and the reprogramming of immune suppression to restore systemic immunological stability. This approach represents a departure from conventional immunotherapy paradigms by asserting that effective immune restoration can be achieved without cellular transplantation or genetic manipulation. The program is primarily targeted at metastatic cancer and solid tumors, and research findings have been presented at major conferences such as SITC 2025.

Brand names: Oncovix
Other names: OncoVix

Beyond the preview

Go deeper on Oncovix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncovix.

Explore the full profile